Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system.

Sinmaz N, Nguyen T, Tea F, Dale RC, Brilot F.

J Neuroinflammation. 2016 Aug 30;13(1):219. doi: 10.1186/s12974-016-0678-4. Review.

2.

DPD epitope-specific glutamic acid decarboxylase (GAD)65 autoantibodies in children with Type 1 diabetes.

Bansal N, Hampe CS, Rodriguez L, O'Brian Smith E, Kushner J, Balasubramanyam A, Redondo MJ.

Diabet Med. 2017 May;34(5):641-646. doi: 10.1111/dme.13077. Epub 2016 Feb 12.

PMID:
26802570
3.

Zinc transporter 8 (ZnT8) autoantibody epitope specificity and affinity examined with recombinant ZnT8 variant proteins in specific ZnT8R and ZnT8W autoantibody-positive type 1 diabetes patients.

Skärstrand H, Krupinska E, Haataja TJ, Vaziri-Sani F, Lagerstedt JO, Lernmark Å.

Clin Exp Immunol. 2015 Feb;179(2):220-9. doi: 10.1111/cei.12448.

4.

Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasis.

Kass I, Hoke DE, Costa MG, Reboul CF, Porebski BT, Cowieson NP, Leh H, Pennacchietti E, McCoey J, Kleifeld O, Borri Voltattorni C, Langley D, Roome B, Mackay IR, Christ D, Perahia D, Buckle M, Paiardini A, De Biase D, Buckle AM.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2524-9. doi: 10.1073/pnas.1403182111. Epub 2014 Jun 9.

5.

A versatile protein microarray platform enabling antibody profiling against denatured proteins.

Wang J, Barker K, Steel J, Park J, Saul J, Festa F, Wallstrom G, Yu X, Bian X, Anderson KS, Figueroa JD, LaBaer J, Qiu J.

Proteomics Clin Appl. 2013 Jun;7(5-6):378-83. doi: 10.1002/prca.201200062. Epub 2013 May 17.

6.

Autoantigen discovery with a synthetic human peptidome.

Larman HB, Zhao Z, Laserson U, Li MZ, Ciccia A, Gakidis MA, Church GM, Kesari S, Leproust EM, Solimini NL, Elledge SJ.

Nat Biotechnol. 2011 May 22;29(6):535-41. doi: 10.1038/nbt.1856.

7.

An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Jayakrishnan B, Hoke DE, Langendorf CG, Buckle AM, Rowley MJ.

PLoS One. 2011 Apr 8;6(4):e18411. doi: 10.1371/journal.pone.0018411.

8.

Two distinct mechanisms target GAD67 to vesicular pathways and presynaptic clusters.

Kanaani J, Kolibachuk J, Martinez H, Baekkeskov S.

J Cell Biol. 2010 Sep 6;190(5):911-25. doi: 10.1083/jcb.200912101. Epub 2010 Aug 30.

9.

Characterisation of peptide microarrays for studying antibody-antigen binding using surface plasmon resonance imagery.

Nogues C, Leh H, Langendorf CG, Law RH, Buckle AM, Buckle M.

PLoS One. 2010 Aug 13;5(8):e12152. doi: 10.1371/journal.pone.0012152.

10.

Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome.

Rizzi M, Knoth R, Hampe CS, Lorenz P, Gougeon ML, Lemercier B, Venhoff N, Ferrera F, Salzer U, Thiesen HJ, Peter HH, Walker UA, Eibel H.

PLoS One. 2010 May 26;5(5):e10838. doi: 10.1371/journal.pone.0010838.

11.

Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies.

Hall TR, Bogdani M, Leboeuf RC, Kirk EA, Maziarz M, Banga JP, Oak S, Pennington CA, Hampe CS.

Immunology. 2008 Apr;123(4):547-54. Epub 2007 Nov 14.

12.
14.

Epitope analysis of insulin autoantibodies using recombinant Fab.

Padoa CJ, Crowther NJ, Thomas JW, Hall TR, Bekris LM, Torn C, Landin-Olsson M, Ortqvist E, Palmer JP, Lernmark A, Hampe CS.

Clin Exp Immunol. 2005 Jun;140(3):564-71.

15.

Multiplicity of the antibody response to GAD65 in Type I diabetes.

Gilliam LK, Binder KA, Banga JP, Madec AM, Ortqvist E, Kockum I, Luo D, Hampe CS.

Clin Exp Immunol. 2004 Nov;138(2):337-41.

16.

Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient.

Banga JP, Moore JK, Duhindan N, Madec AM, van Endert PM, Orgiazzi J, Endl J.

Clin Exp Immunol. 2004 Jan;135(1):74-84.

17.

Distinct antigenic features of linear epitopes at the N-terminus and C-terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis.

Al-Bukhari TA, Radford PM, Bouras G, Davenport C, Trigwell SM, Bottazzo GF, Lai M, Schwartz HL, Tighe PJ, Todd I.

Clin Exp Immunol. 2002 Oct;130(1):131-9.

18.

Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus.

Trigwell SM, Radford PM, Page SR, Loweth AC, James RF, Morgan NG, Todd I.

Clin Exp Immunol. 2001 Nov;126(2):242-9.

19.

Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Powers AC, Bavik K, Tremble J, Daw K, Scherbaum WA, Banga JP.

Clin Exp Immunol. 1999 Dec;118(3):349-56.

Supplemental Content

Support Center